ReviewThe American journal of medicine2012
Amiodarone-associated optic neuropathy: a critical review.
Review in The American journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 84 citations in OpenAlex.
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Guideline
- Neuronal safety of Kv11.1 blockers: Patch-clamp and in vitro evaluation with physiologically based pharmacokinetic (PBPK) modeling.Toxicology reports · 2026Article
- Amiodarone-induced ocular and extra-ocular toxicity: a retrospective cohort study.Clinical and experimental medicine · 2025Observational
- Amiodarone-related keratopathy and optic neuropathy: case report and literature review.Frontiers in medicine · 2025Article
- Advances in Atrial Fibrillation Management: A Guide for General Internists.Journal of clinical medicine · 2024Review
- Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide.American journal of ophthalmology case reports · 2024Article
- Amiodarone Therapy: Updated Practical Insights.Journal of clinical medicine · 2024Review
- Artemisinin conferred cytoprotection to human retinal pigment epithelial cells exposed to amiodarone-induced oxidative insult by activating the CaMKK2/AMPK/Nrf2 pathway.Journal of translational medicine · 2024Article
- Article
- Adverse Ocular Effects of Systemic Medications.Life (Basel, Switzerland) · 2023Review
- Clinical and Mechanistic Review of Amiodarone-Associated Optic Neuropathy.Biomolecules · 2022Review
- Drug-induced corneal deposits: an up-to-date review.BMJ open ophthalmology · 2022Review
- Optic Perineuritis Distinguishing Arteritic Ischaemic from Amiodarone-Associated Optic Neuropathy.Neuro-ophthalmology (Aeolus Press) · 2021Article
- Amiodarone Alters Cholesterol Biosynthesis through Tissue-Dependent Inhibition of Emopamil Binding Protein and Dehydrocholesterol Reductase 24.ACS chemical neuroscience · 2020Article
- Improved Survival in Hepatocellular Carcinoma Patients with Cardiac Arrhythmia by Amiodarone Treatment through Autophagy.International journal of molecular sciences · 2019Article
- Adverse reactions of Amiodarone.Journal of geriatric cardiology : JGC · 2019Review
- Amiodarone-associated Optic Neuropathy-A Clinical Criteria-based Diagnosis?Neuro-ophthalmology (Aeolus Press) · 2018Article
- Amiodarone-Induced Retinal Neuronal Cell Apoptosis Attenuated by IGF-1 via Counter Regulation of the PI3k/Akt/FoxO3a Pathway.Molecular neurobiology · 2017Article
- Amiodarone-Associated Optic Neuropathy: Clinical Review.Neuro-ophthalmology (Aeolus Press) · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
Abstract
Although amiodarone is the most commonly prescribed anti-arrhythmic drug, its use is limited by serious toxicities, including optic neuropathy. Current reports of amiodarone-associated optic neuropathy identified from the Food and Drug Administration's Adverse Event Reporting System and published case reports were reviewed. A total of 296 reports were identified: 214 from the Adverse Event Reporting System, 59 from published case reports, and 23 from adverse events reports for patients enrolled in clinical trials. Mean duration of amiodarone therapy before vision loss was 9 months (range 1-84 months). Insidious onset of amiodarone-associated optic neuropathy (44%) was the most common presentation, and nearly one third were asymptomatic. Optic disk edema was present in 85% of cases. Following drug cessation, 58% had improved visual acuity, 21% were unchanged, and 21% had further decreased visual acuity. Legal blindness (<20/200) was noted in at least one eye in 20% of cases. Close ophthalmologic surveillance of patients during the tenure of amiodarone administration is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.